

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ken LIPSON et al.

Title: METHODS OF MODULATING C-KIT TYROSINE PROTEIN KINASE
FUNCTION WITH INDOLINONE COMPOUNDS

Prior Appl. No.: 09/741,842

Prior Appl. Filing Date: 12/22/2000

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/741,842, filed 12/22/2000. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Date

6/23/03

FOLEY & LARDNER
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5475

Facsimile: (202) 672-5399

Respectfully submitted,

By

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: June 23, 2003

(use as many sheets as necessary)

Complete if Known

Prior Application Number	09/741,842
Prior Appl. Filing Date	12/22/2000
First Named Inventor	Ken Lipson
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	038602-1607

Sheet 1 of 31

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	2,622,980		Copeland	12-23-1952	
	A2	2,872,372		Hull	02-03-1959	
	A3	2,968,557		Burgandt et al.	01-17-1961	
	A4	3,140,180		Fritz	07-07-1964	
	A5	3,308,134		Plostneiks	03-07-1967	
	A6	3,551,571		Pachter et al.	12-29-1970	
	A7	3,564,016		Schoen et al.	02-16-1971	
	A8	3,715,364		Hoff	02-06-1973	
	A9	3,880,871		Haugwitz et al.	04-29-1975	
	A10	3,922,163		Church et al.	11-25-1975	
	A11	4,002,643		Carson	01-11-1977	
	A12	4,002,749		Rovnyak	01-11-1977	
	A13	4,053,613		Rovnyak et al.	10-11-1977	
	A14	4,070,366		Gregorovich et al.	01-24-1978	
	A15	4,259,345		Cross et al.	03-31-1981	
	A16	4,259,346		Helmut STÄHLE et al.	03-31-1981	
	A17	4,343,923		Lenox et al.	08-10-1982	
	A18	4,376,110		David et al.	03-08-1983	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

*Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Prior Application Number	09/741,842
				Prior Appl. Filing Dat	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	038602-1607
Sheet	2	of	31		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A19	4,436,892		Zondler et al.	03-13-1984	
	A20	4,489,089		Wright, Jr. et al.	12-18-1984	
	A21	4,493,642		Furazawa et al.	01-15-1985	
	A22	4,493,842		Kunihiko FURUZAWA et al.	01-15-1985	
	A23	4,628,105		Schmid et al.	12-09-1986	
	A24	4,642,309		Michel et al.	02-10-1987	
	A25	4,826,847		Michel et al.	05-02-1989	
	A26	4,853,403		Shiraishi et al.	08-01-1989	
	A27	4,853,404		Takamura et al.	08-01-1989	
	A28	4,868,304		Larock	09-19-1989	
	A29	4,924,000		Rentzea et al.	05-08-1990	
	A30	4,966,849		Vallee et al.	10-30-1990	
	A31	4,971,996		Shiraishi et al.	11-20-1990	
	A32	4,987,146		Rohde et al.	01-22-1991	
	A33	5,043,348		Zoller et al.	08-27-1991	
	A34	5,043,454		Wriede et al.	08-27-1991	
	A35	5,047,554		Ehrgott et al.	09-10-1991	
	A36	5,051,417		Nadler et al.	09-24-1991	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: June 23, 2003

(use as many sheets as necessary)

Complete if Known

Prior Application Number	09/741,842
Prior Appl. Filing Date	12/22/2000
First Named Inventor	Ken Lipson
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	038602-1607

Sheet 3 of 31

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A37	5,057,538		Shiraishi et al.	10-15-1991	
	A38	5,082,856	A	Taniguchi et al.	01-21-1992	
	A39	5,082,856	A	Masao TANIGUCHI et al.	01-21-1992	
	A40	5,089,516	A	Shiraishi et al.	02-18-1992	
	A41	5,124,347	A	Connor et al.	06-23-1992	
	A42	5,145,983	A	West	09-08-1992	
	A43	5,153,217	A	Taniguchi et al.	10-06-1992	
	A44	5,196,446	A	Levitzi et al.	03-23-1993	
	A45	5,202,341	A	Shiraishi et al.	04-13-1993	
	A46	5,206,261	A	Kawaguchi et al.	04-27-1993	
	A47	5,217,999	A	Levitzi et al.	06-08-1993	
	A48	5,258,357	A	Muenster et al.	11-02-1993	
	A49	5,278,184	A	Artico et al.	01-11-1994	
	A50	5,290,947	A	Zoller et al.	03-01-1994	
	A51	5,302,606	A	Spada et al.	04-12-1994	
	A52	5,322,950	A	Sircar et al.	06-21-1994	
	A53	5,330,992	A	Eissenstat et al.	07-19-1994	
	A54	5,332,736	A	Carmosin et al.	07-26-1994	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

Date Submitted: June 23, 2003

(use as many sheets as necessary)

Complete if Known

Prior Application Number	09/741,842
Prior Appl. Filing Date	12/22/2000
First Named Inventor	Ken Lipson
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	038602-1607

Sheet 4 of 31

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A55	5,374,652	A	Buzzetti et al.	12-20-1994	
	A56	5,382,593	A	Le Baut et al.	01-17-1995	
	A57	5,389,661	A	Sircar et al.	02-14-1995	
	A58	5,397,787	A	Buzzetti et al.	03-14-1995	
	A59	5,409,930	A	Spada et al.	04-25-1995	
	A60	5,409,949	A	Buzzetti et al.	04-25-1995	
	A61	5,463,052	A	Haga et al.	10-31-1995	
	A62	Re. 35,096	E	Taniguchi et al.	11-21-1995	
	A63	5,565,324	A	Still et al.	10-15-1996	
	A64	5,610,173	A	Schwartz et al.	03-11-1997	
	A65	5,723,665	A	Kato et al.	03-03-1998	
	A66	5,786,488	A	Tang et al.	07-28-1998	
	A67	5,792,783		tang et al.	08-11-1998	
	A68	5,792,783	A	Tang et al.	08-11-1998	
	A69	5,834,504	A	Tang et al.	11-10-1998	
	A70	5,849,710	A	Battistini et al.	12-15-1998	
	A71	5,880,141		tang et al.	03-09-1999	
	A72	5,880,141	A	Tang et al.	03-09-1999	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

*Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Prior Application Number	09/741,842
				Prior Appl. Filing Dat	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	038602-1607
Sheet	5	of	31		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A73	5,883,113	A	Tang et al.	03-16-1999	
	A74	5,883,116	A	Tang et al.	03-16-1999	
	A75	5,886,020	A	Tang et al.	03-23-1999	
	A76	Re. 36,256	E	Spada et al.	07-20-1999	
	A77	6,130,239	A	Chen et al.	10-10-2000	
	A78	6,133,305	A	Tang et al.	10-17-2000	
	A79	6,284,894	B1	Phillion et al.	09-04-2001	
	A80	6,310,217	B1	Lehr	10-30-2001	
	A81	6,395,736	B1	Thomas PARKS et al.	05-28-2002	
	A82	6,451,838	B1	Malcolm Wilson MOON et al.	09-17-2002	
	A83	6,462,072	B1	Gregory HAMILTON et al.	10-08-2002	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A84	WO	88/07035	A1	KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA	09-22-1988		
	A85	WO	91/13055	A2	FARMITALIA CARLO ERBA SRL	09-05-1991		
	A86	WO	91/15495	A1	PFIZER INC.	10-17-1991		

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

*Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 <i>(use as many sheets as necessary)</i>				Complete if Known		
				Prior Application Number		09/741,842
				Prior Appl. Filing Date		12/22/2000
				First Named Inventor		Ken Lipson
				Group Art Unit		Unassigned
				Examiner Name		Unassigned
				Attorney Docket Number		038602-1607
Sheet	6	of	31			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A87	WO	92/03736	A1	SEIKAGAKU KOGYO KABUSHIKI KAISHA	03-05-1992		
	A88	WO	92/07830	A2	PFIZER INC.	05-14-1992		
	A89	WO	92/20642	A1	RHONEPOULENC RORER INTERNATIONAL	11-26-1992		
	A90	WO	92/21660	A1	PFIZER INC.	12-10-1992		
	A91	WO	93/01182	A1	FARMITALIA CARLO ERA SRL	01-21-1993		
	A92	WO	93/23040	A1	MERCK & CO., INC.	11-25-1993		
	A93	WO	94/03427	A1	WARNER-LAMBERT COMPANY	02-17-1994		
	A94	WO	94/10202	A1	GENENTECH, INC.	05-11-1994		
	A95	WO	94/14808	A1	FARMITALIA CARLO ERBA SRL	07-07-1994		
	A96	WO	95/01349	A1	FARMITALIA CARLO ERBA SRL	01-12-1995		
	A97	WO	95/14667	A1	PFIZER INC.	06-01-1995		
	A98	WO	95/17181	A1	PHARMACIA S.P.A.	06-29-1995		
	A99	WO	95/24190	A2	SUGEN, INC.	09-14-1995		
	A100	WO	96/00226	A1	PHARMACIA S.P.A.	01-04-1996		
	A101	WO	96/16964	A1	PHARMACIA S.P.A.	06-06-1996		
	A102	WO	96/22976	A1	PHARMACIA S.P.A.	08-01-1996		
	A103	WO	96/32380	A1	PHARMACIA S.P.A.	10-17-1996		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

Date Submitted: June 23, 2003

(use as many sheets as necessary)

Complete if Known

Prior Application Number	09/741,842
Prior Appl. Filing Date	12/22/2000
First Named Inventor	Ken Lipson
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	038602-1607

Sheet 7 of 31

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A104	WO	96/40116	A1	SUGEN, INC.	12-19-1996		
	A105	WO	97/25986	A1	TAIHO PHARMACEUTICAL CO., LTD.	07-24-1997		
	A106	WO	97/34920	A1	SUGEN, INC.	09-25-1997		
	A107	WO	97/36867	A1	PFIZER, INC.	10-09-1997		
	A108	WO	98/07695	A1	SUGEN, INC.	02-26-1998		
	A109	WO	98/07835	A2	SUGEN, INC.	02-26-1998		
	A110	WO	98/24432	A2	SUGEN, INC.	06-11-1998		
	A111	WO	98/38984	A2	SUGEN, INC.	09-11-1998		
	A112	WO	98/45708	A1	SUGEN, INC.	10-15-1998		
	A113	WO	98/50356	A1	SUGEN, INC.	11-12-1998		
	A114	WO	98/56376	A1	SUGEN, INC.	12-17-1998		
	A115	WO	99/10325	A1	GLAXO GROUP LIMITED	03-04-1999		
	A116	WO	99/19325	A1	SYNTHELABO	04-22-1999		
	A117	WO	99/48868	A2	SUGEN, INC.	09-30-1999		
	A118	WO	99/52869	A1	BOEHRINGER INGELHEIM PHARMA KG	10-21-1999		
	A119	WO	99/61422	A1	SUGEN, INC.	12-02-1999		
	A120	WO	99/65869	A1	BAYER AKTIENGESELLSCHAFT	12-23-1999		
	A121	WO	00/08202	A2	SUGEN, INC.	02-17-2000		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

Date Submitted: June 23, 2003

(use as many sheets as necessary)

Complete if Known

Prior Application Number	09/741,842
Prior Appl. Filing Date	12/22/2000
First Named Inventor	Ken Lipson
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	038602-1607

Sheet 8 of 31

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A122	WO	00/38519	A1	SUGEN, INC.	07-06-2000		
	A123	WO	00/56709	A1	SUGEN, INC.	09-28-2000		
	A124	WO	01/60814	A2	SUGEN, INC.	08-23-2001		
	A125	DE	878,539		Von FREYBERG, et al.	06-05-1953		
	A126	DE	2,159,360	A	BAYER AG	06-14-1973		
	A127	DE	2,159,361	A	BAYER AG	06-14-1973		
	A128	DE	2,159,362		BAYER AG	06-14-1973		
	A129	DE	2,159,363	A	BAYER AG	06-14-1973		
	A130	DE	2,321,656	A	COLGATE-PALMOLIVE CO.	11-15-1973		
	A131	DE	3,426,419	A	BOEHRINGER MANNHEIM GMBH	01-23-1986		
	A132	EP	0 252 713	B1	PFIZER INC.	01-13-1988		
	A133	EP	0 304 493	B1	KANEGAFUCHI KAGAKU KOGTO KABUSHIKI KAISHA	03-01-1989		
	A134	EP	0 351 213	A2	LES LABORATOIRES BEECHAM S.A.	01-17-1990		
	A135	EP	0 525 472	A2	FARMITALIA CARLO ERBA SRL	02-03-1993		
	A136	EP	0 566 226	B1	ZENECA LIMITED	10-20-1993		
	A137	EP	0 580 502	B1	ADIR ET COMPAGNIE	01-26-1994		
	A138	EP	0 626 377	B1	SHIONOGI & CO., LTD.	11-30-1994		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 <i>(use as many sheets as necessary)</i>				Complete if Known		
				Prior Application Number		09/741,842
				Prior Appl. Filing Date		12/22/2000
				First Named Inventor		Ken Lipson
				Group Art Unit		Unassigned
				Examiner Name		Unassigned
				Attorney Docket Number		038602-1607
Sheet	9	of	31			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A139	EP	0 632 102	A1	BAYER AG	01-04-1995		
	A140	EP	0 662 473	A1	PHARMACIA S.P.A.	07-12-1995		
	A141	EP	0 788 890	A1	AGFA-GEVAERT	08-13-1997		
	A142	EP	0 810 217	A1	JAPAN ENERGY CORPORATION	12-03-1997		
	A143	EP	0 769 947	B1	TANG, Peng Cho et al.	05-02-1997		
	A144	EP	0 934 931	A2	SUGEN, INC.	08-11-1999		
	A145	EP	1 082 305	A1	SUGEN, INC.	03-14-2001		
	A146	FR	1.398.224		IMPERIAL CHEMICAL INDUSTRIES LIMITED	05-07-1965		
	A147	FR	1.599.772		INSTITUT PASTEUR	08-28-1970		
	A148	FR	2.689.397	A1	ADIR ET COMPAGNIE	10-08-1993		
	A149	GB	809,691		Roy HULL	03-04-1959		
	A150	GB	835,473		Norman SENIOR	05-18-1960		
	A151	JP	62-29570	A	KANEGAFUCHI CHEM KK	02-07-1987		
	A152	JP	62-39564	A	KANEGAFUCHI CHEM KK	02-20-1987		
	A153	JP	63-141955	A	KANEGAFUCHI CHEM KK	06-14-1988		
	A154	JP	5-58894	A	KANEKA CORP	03-09-1993		
	A155	CA	2,012,634	A1	UNIVERSITY OF BRITISH COLUMBIA	09-20-1991		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 <i>(use as many sheets as necessary)</i>				Prior Application Number	09/741,842
				Prior Appl. Filing Dat	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	10	of	31	Attorney Docket Number	038602-1607

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A156	AU	286870		IMPERIAL CHEMICAL INDUSTRIES OF AUSTRALIA AND NEW ZEALAND LIMITED	05-11-1967		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	A157	ABRAMOVITCH and HEY, "Internuclear cyclisation. Part VIII. Naphth[3:2:1-cd]oxindoles," <u>J. Chem. Soc.</u> 1697-1703 (1954), Strand, London		
	A158	ABRAMOVITCH et al., "A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement," <u>Chemistry and Industry</u> 44:1871 (1967) ©Laporte Industries Limited, Lancashire		
	A159	Beilstein Reg. No. 236050, Beilstein Reference No. 4-21-00-06355		
	A160	AKBASAK and SUNAR-AKBASAK, "Oncogenes: cause or consequence in the development of glial tumors," <u>J. Neurol. Sci.</u> 111:119-133 (1992)© Elsevier Science Publishers		
	A161	ANDREANI et al., "Potential Antitumor Agents. 25[1]. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3-Indolymethylene)1,3-Dihydroindol-2-Ones," <u>Anticancer Research</u> 16:3585-3588 (1996) © Elsevier, Paris		
	A162	ANDREANI et al., "Synthesis and cardiotoxic activity of 2-indolinones," <u>Eur. J. Med. Chem.</u> 25:187-190 (1990)		
	A163	ANDREANI et al., "Synthesis and cardiotoxic activity of 2-indolinones bearing pyridyl groups," <u>Eur. J. Med. Chem.</u> 28:653-657 (1993) © Elsevier, Paris		
	A164	ANDREANI et al., "Synthesis and cardiotoxic activity of 2-indolinones," <u>Chemical Abstracts</u> , Vol. 113, abstract no. 78106 (1990)		
	A165	ANDREANI et al., "Synthesis and cardiotoxic activity of pyridylmethylene-2-indolinones," <u>Eur. J. Med. Chem.</u> 27:167-170 (1992) © Elsevier, Paris		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

*Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

Date Submitted: June 23, 2003

(use as many sheets as necessary)

Complete if Known

Prior Application Number	09/741,842
Prior Appl. Filing Date	12/22/2000
First Named Inventor	Ken Lipson
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	038602-1607

Sheet 11 of 31

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A166	ANDREANI et al., "Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones," <u>Eur. J. Med. Chem.</u> 32:919-924 (1997)® Elsevier, Paris	
	A167	ANDREANI et al., "Synthesis of lactams with potential cardiotonic activity," <u>Eur. J. Med. Chem.</u> 28:825-829 (1993)	
	A168	ANDREANI et al., "In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones," <u>Arzneimittel-Forschung Drug Research</u> 48:727-729 (1998)®	
	A169	ARTEAGA et al., "Blockade of the Type I Somatostatin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," <u>J. Clin. Invest.</u> 84:1418-1423 (1989) copyright The American Society for Clinical investigation, Inc.	
	A170	ARVIDSSON et al., "Tyr-716 in the Platelet-Derived Growth Factor β -Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," <u>Molecular and Cellular Biology</u> 14:6715-6726 (1994)® The American Society for Microbiology	
	A171	AUTREY and TAHK, "The Synthesis and Stereochemistry of Some Isatylideneacetic Acid Derivatives," <u>Tetrahedron</u> 23:901-917 (1967)®Pergamon Press	
	A172	BAHNER and BROTHERTON, "9-(4-Aminobenzylidene)fluorenes," <u>J. Med. Chem.</u> 12:722-723 (1969)	
	A173	BAHNER et al., "Benzylideneindenes with Oxygen Attached to the Indene Ring," <u>J. Med. Chem.</u> 12:721-722 (1969)	
	A174	BAMFIELD et al., "Diels-Alder Reactions of Oxindolylideneacetone," <u>J. Chem. Soc. (C)</u> 1028-1030 (1966)®	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 (use as many sheets as necessary)				Complete if Known	
				Prior Application Number	09/741,842
				Prior Appl. Filing Date	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	038602-1607
Sheet	12	of	31		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	A175	BARBIER, et al., "Synthesis of Isobrassilexin, A Biologically Active Isomer of Brassilexin, a Cruciferae Phytoalexin," <u>Synthetic Communications</u> 23(22):3109-3117 (1993) © Marcel Dekker, Inc.		
	A176	BASERGA, "Oncogenes and the Strategy of Growth Factors," <u>Cell</u> 79:927-930 (1994) © Cell Press		
	A177	BASERGA, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" <u>Cancer Research</u> 55:249-252 (1995)		
	A178	Beilstein Reg. No. 233511 (1997)		
	A179	Beilstein Reg. No. 235647 (1997)		
	A180	Beilstein Reg. No. 252929 (1998)		
	A181	BENZIES, et al., "2-Formyl-3-Methoxymethylindole, 3-Ethoxymethyl-2-Formylindoline and 2-Formyl-3-Methylindole," <u>Synthetic Communications</u> : 16(14), 1799-1807 (1986) © Mercel Dekker, Inc.		
	A182	BLAKE and JAQUES, "Anisotropic Effects in α -Substituted Methoxystilbenes," <u>J. Chem. Soc. Perkin II</u> : 1660-1663 (1973) © Pergamon, Oxford		
	A183	BOLEN et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB J.</u> 6:3403-3409 (1992)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 (use as many sheets as necessary)				Prior Application Number	09/741,842
				Prior Appl. Filing Date	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	13	of	31	Attorney Docket Number	038602-1607

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	A184	BOLEN, "Nonreceptor tyrosine protein kinases," <u>Oncogene</u> 8:2025-2031 (1993) copyright MacMillan Press Ltd.			
	A185	BONNER et al., "Structure and Biological Activity of Human Homologs of the <i>raf/mil</i> Oncogene," <u>Molecular and Cellular Biology</u> 5:1400-1407 (1985) © The American Society for Microbiology			
	A186	BORSCHKE et al., "Über vielkernige kondensierte Systeme mit heterocyclischen Ringen. XIII.," <u>Liebigs Ann. Chem.</u> 550:160-174 (1941)			
	A187	BUZZETTI et al., "Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," <u>Il Farmaco</u> 48:615-636 (1993)			
	A188	CANCE et al., "Novel Protein Kinases Expressed in Human Breast Cancer," <u>Int. J. Cancer</u> 54:571-577 (1993) © Wiley-Liss, Inc.			
	A189	CANOIRA and RODRIGUEZ, "Synthesis of Oxindole Derivatives from N-Alkenyl-o-Chloroanilides with Zero-Valent Nickel Complex," <u>J. Heterocyclic Chem.</u> 22:1511-1518 (1985)			
	A190	CARPENEDO et al., "Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs," <u>Analytical Biochemistry</u> 244:74-79 (1997) © Academic Press, Inc.			
	A191	CHAO, "Growth Factor Signaling: Where Is the Specificity?" <u>Cell</u> 68:995-997 (1992) copyright Cell Press			
	A192	CHATTEN et al., "Substituted Oxindoles. Part VI. Polarographic Reduction of Substituted <i>trans</i> -3-Benzylideneindol-2(3 <i>H</i>)-ones," <u>J. Chem. Soc. Perkin II</u> : 469-473 (1973)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 <i>(use as many sheets as necessary)</i>				Prior Application Number	09/741,842
				Prior Appl. Filing Date	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	14	of	31	Attorney Docket Number	038602-1607

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	A193	CHATTERJEE, et al., "Acylation of Indoles by Duff Reaction and Vilsmeier-Haack Formylation and Conformation of N-Formylindoles," <u>J. Org. Chem.</u> , 38:4002-4004 ©The American Chemical Society		
	A194	CHEN et al., "Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on γ -Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron," <u>Chinese Journal of Physiology</u> 40:149-156 (1997)		
	A195	CLAESSON-WELSH, "Signal Transduction by the PDGF Receptors," <u>Progress in Growth Factor Research</u> 5:37-54 (1994) © Elsevier Science Ltd.		
	A196	CODA et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," <u>J. Chem. Soc. Perkin Trans. II</u> : 615-619 (1984)		
	A197	CODA et al., "3-(4-methylbenzylidene)-1,3-dihydroindol-2-one," <u>Journal of the Chemical Society, Perkin Transactions 2</u> 4:615-620 (1984) DATABASE CROSSFIRE, Beilstein Reference No. 6-21		
	A198	COPPOLA et al., "A Functional Insulin-Like Growth Factor I Receptor Is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 14:4588-4595 (1994) © The American Society for Microbiology		
	A199	DAISLEY and WALKER, "Thin-layer chromatographic separation of some substituted 3-benzylidene-indol-2(3H)-ones," <u>J. Chromatography</u> 100:240-242 (1974) © Elsevier Scientific Publishing Company		
	A200	DAMIANI et al., "Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals," <u>Biochemical Pharmacology</u> 48:1155-1161 (1994) copyright Elsevier Science Ltd.		
	A201	DATI et al., "Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells," <u>Oncogene</u> 5:1001-1006 (1990)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

*Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 (use as many sheets as necessary)				Complete if Known	
				Prior Application Number	09/741,842
				Prior Appl. Filing Date	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	038602-1607
Sheet	15	of	31		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	A202	DAVIS et al., "Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds," <u>Journal of Medicinal Chemistry</u> 16:1043-1045 (1973) ©American Chemical Society		
	A203	DE VRIES et al., "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255:989-991 (1992)		
	A204	DECKER and LOHMANN-MATTHES, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," <u>J. Immunol. Methods</u> 15:61-69 (1988) copyright Elsevier		
	A205	DECODTS et al., "Suicide inhibitors of proteases. Lack of activity of halomethyl derivatives of some aromatic lactams," <u>Eur. J. Med. Chem</u> 18: 107-111 (1983)		
	A206	DESIMONI et al., "Catalysis with Inorganic Cations. V ¹ Intramolecular Hetero Diels-Alder versus Ene Reactions: Effect of Magnesium perchlorate on Chemoselectivity," <u>Tetrahedron</u> 52(36) 12009-12018 (1996) © Pergamon		
	A207	DICKSON et al., "13. Tyrosine kinase receptor - nuclear protooncogene interactions in breast cancer," <u>Cancer Treatment Res.</u> 61:249-273 (1992) © Kluwer Academic Publishers		
	A208	ELLIOTT and RIVERS, "Reduction of Some Oxindolylidene Derivatives to 3-Substituted Oxindoles by Sodium Borohydride," <u>J. Med. Chem.</u> 29:2438-2440 (1964)		
	A209	ELLIOTT et al., "1-methyl-2-(3-oxindolidenmethyl)-pyridinium," <u>Journal of Organic Chemistry</u> 29:2438-2440 (1964) DATABASE CROSSFIRE, Beilstein Reference No. 5-24		
	A210	FANTL et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," <u>Cell</u> 69:413-423 (1992) © Cell Press		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	09/741,842
				Prior Appl. Filing Date	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Date Submitted: June 23, 2003				Attorney Docket Number	038602-1607
(use as many sheets as necessary)					
Sheet	16	of	31		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	A211	FENDLY et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product, <u>Cancer Research</u> 50:1550-1558 (1990); @ American Association for Cancer Research			
	A212	FERRARA and HENZEL, "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochemical and Biophysical Research Communications</u> 161:851-858 (1989) © Academic Press, Inc.			
	A213	FINGL and WOODBURY, "Chapter 1 - General Principles," in <u>The Pharmacological Basis of Therapeutics</u> 5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975) © MacMillan Publishing Co. Inc.			
	A214	FLOEGE et al., "Factors involved in the regulation of mesangial cell proliferation <i>in vitro</i> and <i>in vivo</i> ," <u>Kidney International</u> 43:S47-S54 (1993) © International Society of Nephrology			
	A215	FLOEGE et al., "Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis," <u>Kidney International</u> 43:369-380 (1993) © International Society of Nephrology			
	A216	FOLKMAN and SHING, "Angiogenesis," <u>J. Biol. Chem.</u> 267:10931-10934 (1992) © The American Society for Biochemistry and Molecular Biology			
	A217	FOLKMAN, "Ch. 24. Angiogenesis," <u>Congress of Thrombosis and Haemostasis</u> (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987)			
	A218	FOLKMAN, "Tumor Angiogenesis: Therapeutic Implications," <u>New England J. Medicine</u> 285:1182-1186 (1971)			
	A219	FOLKMAN, "What is the Evidence that Tumors are Angiogenesis Dependent?" <u>Journal of the National Cancer Institute</u> 82:4-6 (1990)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 <i>(use as many sheets as necessary)</i>				Prior Application Number	09/741,842
				Prior Appl. Filing Date	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	17	of	31	Attorney Docket Number	038602-1607

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	A220	FOLKMAN, "Angiogenesis in Psoriasis: Therapeutic Implications," <u>J. Invest. Dermatol.</u> 59:40-43 (1973) copyright The Williams & Wilkins Co.			
	A221	GAZIT et al., "Tyrophostins. 2. Heterocyclic and α -Substituted Benzylidenemalononitrile Tyrophostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," <u>J. Med. Chem.</u> 34:1896-1907 (1991) copyright Am. Chem. Soc.			
	A222	GENNARO (editor), <u>Remington's Pharmaceutical Sciences</u> (1990) (TABLE OF CONTENTS ONLY)			
	A223	GOLDRING and GOLDRING, "Cytokines and Cell Growth Control," <u>Critical Reviews in Eukaryotic Gene Expression</u> 1:301-326 (1991)			
	A224	GOTTARDIS et al., "Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumorstatic Action of Tamoxifen," <u>J. Steroid Biochem.</u> 30:311-314 (1988) © Pergamon Press			
	A225	GRAZIANI et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger," <u>The Journal of Biological Chemistry</u> 268:9165-9168 (1993) ©American Society for Biochemistry and Molecular Biology			
	A226	HAYLER et al., Development of Large-Scale Syntheses of Ropinirole in the Pursuit of a Manufacturing Process," <u>Organic Process Research & Development</u> 2(1) 3-9 (1998) ©The American Chemical Society and Royal Society of Chemistry			
	A227	HEWGILL and STEWART, "Phenanthrene-4,5-quinones: a Synthesis of Morphenol," <u>J. Chem. Soc. Perkin Trans. I</u> :1305-1311 (1988)			
	A228	HIRAO et al., "Rhodium-Catalyzed Carbonylation of 2-Alkynylaniline: Syntheses of 1,3-Dihydroindol-2-ones," <u>Tetrahedron Letters</u> 36(35) 1995 ©Pergamon			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Completeness if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Prior Application Number	09/741,842
				Prior Appl. Filing Date	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Date Submitted: June 23, 2003				Attorney Docket Number	038602-1607
(use as many sheets as necessary)					
Sheet	18	of	31		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A229	HODGES et al., "Chemical and biological properties of some oxindolidyl-3-methines," <u>Canadian J. Chemistry</u> 46:2189-2194 (1968)	
	A230	HONEGGER et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 51:199-209 (1987) © Cell Press	
	A231	HOUCK et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," <u>J. Biol. Chem.</u> 267:26031-26037 (1992) © American Society for Biochemistry and Molecular Biology, Inc.	
	A232	HOWARD, Harry R., "Lactam Derivatives," U.S. Provisional Patent Application Number 60/015134	
	A233	HOWARD et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1-acetic acids," <u>Eur. J. Med. Chem.</u> 27:779-789 (1992) © Elsevier, Paris	
	A234	HU et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors," <u>Molecular and Cellular Biology</u> 12:981-990 (1992) copyright Am. Soc. Microbiol.	
	A235	IJAZ et al., "The Conversion of α,β -Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones," <u>J. Chem. Res. (S)</u> : 116 (1990)	
	A236	JELLINEK et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994) © American Chemical Society	
	A237	KASHISHIAN and COOPER, "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase C γ 1," <u>Molecular Biology of the Cell</u> 4:49-57 (1993) © The American Society for Cell Biology	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 <i>(use as many sheets as necessary)</i>				Prior Application Number	09/741,842
				Prior Appl. Filing Dat	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	19	of	31	Attorney Docket Number	038602-1607

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	A238	KASHISHIAN et al., "Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase <i>in vivo</i> ," <u>The EMBO Journal</u> 11:1373-1382 (1992)			
	A239	KATO et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography," <u>Journal of Chromatography</u> 616:67-71 (1993) ©Elsevier Science			
	A240	KATRITZKY et al., "Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues," <u>J. Heterocyclic Chem.</u> 25:1287-1292 (1988)			
	A241	KAZLAUSKAS et al., "The 64-kDa protein that associates with the platelet-derived growth factor receptor β subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp," <u>Proc. Natl. Acad. Sci. USA</u> 90:6939-6942 (1993)			
	A242	KENDALL and THOMAS, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <u>Proc. Natl. Acad. Sci. USA</u> 90:10705-10709 (1993)			
	A243	KHALIL and ABDEL-RAHMAN, "Synthesis of New Mero- and Asymmetrical Pyrazolo-Monomethine Cyanine Dyes," <u>J. Indian Chem. Soc.</u> 54:904-907 (1977) ©The Indian Chemical Society			
	A244	KIKUMOTO et al., "The Reactions of Oxindoles and Isatin with Nitrobenzyl Chlorides," <u>Tetrahedron</u> 22: 3337-3343 (1966) ©Pergamon Press Ltd.			
	A245	KIM et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <u>Nature</u> 362:841-844 (1993)			
	A246	KINSELLA et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," <u>Exp. Cell Research</u> 199:56-62 (1992) © Academic Press, Inc.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 <i>(use as many sheets as necessary)</i>				Prior Application Number	09/741,842
				Prior Appl. Filing Date	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	20	of	31	Attorney Docket Number	038602-1607

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	A247	KLAGSBRUN and SOKER, "VEGF/VPF: the angiogenesis factor found?" <u>Current Biology</u> 3:699-702 (1993) ©Current Biology		
	A248	KOBAYASHI et al., "Anti-tumor Activity of Indole Derivatives," <u>Yakugaku Zasshi</u> 97:1033-1039 (1977)		
	A249	KOCH et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," <u>Science</u> 252:668-674 (1991)		
	A250	KOHLER and MILSTEIN, "Continuous cultures of fused cells secreting antibody of predefined specificity," <u>Nature</u> 256:495-497 (1975)		
	A251	KOMADA and KITAMURA, "The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor," <u>Oncogene</u> 8:2381-2390 (1993)		
	A252	KORC et al., "Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer Is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha," <u>J. Clin. Invest.</u> 90:1352-1360 (1992) copyright The American Society for Clinical Investigation, Inc.		
	A253	KORZENIEWSKI and CALLEWAERT, "An Enzyme-Release Assay for Natural Cytotoxicity," <u>J. Immunol. Methods</u> 64:313-320 (1983) © Elsevier Science Publishers		
	A254	KOVAC and STETINOVA, "Furan derivatives. LXXX. Synthesis and properties of substituted furfurylidenoxindoles," <u>Chem. resu</u> 30:484-492 (1976)		
	A255	KRUEGER and SAITO, "A human transmembrane protein-tyrosine-phosphatase, PTPb, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases," <u>Proc. Natl. Acad. Sci. USA</u> 89:7417-7421 (1992)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 (use as many sheets as necessary)				Complete if Known	
				Prior Application Number	09/741,842
				Prior Appl. Filing Dat	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	038602-1607
Sheet	21	of	31		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	A256	KUMABE et al., "Amplification of α -platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," <u>Oncogene</u> 7:627-633 (1992)		
	A257	LAL et al., "Novel Diuretic Agents: Syntheses of Substituted Isatylidenes & 3-Alkyl or 3-Arylalkyl-2-oxindoles," <u>Indian Journal of Chemistry</u> 13: 898-903 (1975)		
	A258	LAROCK and BABU, "Synthesis of Nitrogen Heterocycles via Palladium-catalyzed Intramolecular Cyclization," <u>Tetrahedron Letters</u> 28:5291-5294 (1987) copyright Pergamon Journals Ltd.		
	A259	LEE and DONOGHUE, "Intracellular Retention of Membrane-Anchored v-s/s Protein Abrogates Autocrine Signal T transduction," <u>J. Cell. Biol.</u> 118:1057-1070 (1992) ©The Rockefeller University Press		
	A260	LEVITZKI and GAZIT, "Tyrosine Kinase Inhibition: An Approach to Drug Development," <u>Science</u> 267:1782-1788 (1995)		
	A261	MA et al., "Indolinone Derivatives Inhibit Constitutively Activated KIT Mutants and Kill Neoplastic Mast Cells," <u>The Journal of Investigative Dermatology</u> , February 2000, pp. 392-394, Vol. 114, No. 2, © The Society for Investigative Dermatology, Inc., USA		
	A262	MAASS et al., "Viral Resistance to the Thiazolo-Iso-Indolinones, a New Class of Nonnucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <u>Antimicrobial Agents and Chemotherapy</u> 37:2612-2617 (1993) ©American Society for Microbiology		
	A263	MACAULAY et al., "Autocrine Function for Insulin-like Growth Factor I in Human Small Cell Lung Cancer Cell Lines and Fresh Tumor Cells," <u>Cancer Research</u> 50:2511-2517 (1990)		
	A264	MARIANI et al., "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," <u>Experimental Therapeutics - Proceedings of the American Association for Cancer Research</u> 35:381 at abstract no. 2268 (March 1994)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

*Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 <i>(use as many sheets as necessary)</i>				Prior Application Number	09/741,842
				Prior Appl. Filing Date	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Attorney Docket Number	038602-1607				
Sheet	22	of	31		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	A265	MARTIN-LEON et al., "On the Cyclization to the Elusive Amino-4H-pyran Ring Some New Facts," <u>Liebigs Ann. Chem.</u> 101-104 (1990) copyright VCH Verlagsgesellschaft mbH ©VCH		
	A266	MEL'NIKOVA TV et al., "Indole chemistry. XXXVIII. Cleavage of a carbon-carbon bond during the reaction of 2-aminoindoles with difunctional compounds," <u>Chemical Abstracts</u> 80 (1974) Abstract No. 003413		
	A267	MILLAUER et al., "High Affintiy VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <u>Cell</u> 72:835-846 (1993) © Cell Press		
	A268	MOHAMMADI et al., "Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors," <u>Science</u> 276:955-960 (1997) © American Association for the Advancement of Science		
	A269	MORETO et al., "Study of the Laxative Properties of the Disodium Salt of the Sulfuric Diester of 3,3 Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (DAN-603) in the Rat," <u>European Journal of Pharmacology</u> 36:221-226 (1976) ©North-Holland Publishing Company		
	A270	MORETO et al., "3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (BHMI), the Active Metabolite of the Laxative Sulisatin," <u>Arzneimittel-Forschung Drug Research</u> 29:1561-1564 (1979)		
	A271	MORRISON et al., "Signal Transduction From Membrane to Cytoplasm: Growth Factors and Membrane-Bound Oncogene Products Increase Raf-1 Phosphorylation and Associated Protein Kinase Activity," <u>Proc. Natl. Acad. Sci. USA</u> 85:8855-8859 (1988)		
	A272	MOSMANN, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <u>J. Immunol. Methods</u> 65:55-63 (1983) copyright Elsevier Publishers B.V.		
	A273	NEBER and RÖCKER, "On the action of benzaldehydes on the free o-aminophenylacetic acid (II)," <u>Chem. Ber.</u> 56:1710-1716 (1923) (GERMAN AND ENGLISH TRANSLATION)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 <i>(use as many sheets as necessary)</i>				Prior Application Number	09/741,842
				Prior Appl. Filing Date	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Attorney Docket Number	038602-1607				
Sheet	23	of	31		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	A274	NISHIMURA et al., "Two Signaling Molecules Share a Phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 13:6889-6896 (1993)			
	A275	NODIFF et al., "Antimalarial Phenanthrene Amino Alcohols. 1. Fluorine-Containing 3- and 6-Substituted 9-Phenanthrenemethanols," <u>J. Med. Chem.</u> 14:921-925 (1971)			
	A276	NODIFF et al., "Antimalarial Phenanthrene Amino Alcohols. 3. Halogen-containing 9-phenanthrenemethanols," <u>Chemical Abstracts</u> , Vol. 83, abstract no. 188214 (1975)			
	A277	OSBORNE et al., "Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," <u>Cancer Research</u> 45:584-590 (1985)			
	A278	O'SULLIVAN and ROTHERY, "The Preparation and Possible Clinical Significance of 4'-Dialkylaminoisoindogenides," <u>Clinica Chimica Acta</u> 62:181-182 (1975) ©Elsevier Scientific Publishing Company			
	A279	OZZELLO and SORDAT, "Behavior of Tumors Produced by Transplantation of Human Mammary Cell Lines in Athymic Nude Mice," <u>Eur. J. Cancer</u> 16:553-559 (1980)			
	A280	PAVLENKO et al., "Introduction of aminomethyl groups into heterocyclic CH-acid molecules," <u>Dopov. Akad. Nauk Ukr Rsr, Ser. B: Geol., Khim. Biol. Nauki</u> 7:64-66 (1980) We should add that we are Sub. Abstract			
	A281	PERKIN et al., "Harmine and Harmaline. Part II. The Synthesis of isoHarman," <u>J. Chem. Soc.</u> 103:1973-1985 (1913)			
	A282	PLATE et al., "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gliomas in vivo," <u>Nature</u> 359:845-848 (1992)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 <i>(use as many sheets as necessary)</i>				Prior Application Number	09/741,842	
				Prior Appl. Filing Date	12/22/2000	
				First Named Inventor	Ken Lipson	
				Group Art Unit	Unassigned	
				Examiner Name	Unassigned	
Attorney Docket Number	038602-1607					
Sheet	24	of	31			

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	A283	PLOWMAN et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," <u>DN&P</u> 7:334-339 (1994)			
	A284	QUALLICH et al., "A General Oxindole Synthesis," <u>J. Synthetic Organic Chemistry</u> : 51-51 (1993)			
	A285	QUINN et al., "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium," <u>Proc. Natl. Acad. Sci. USA</u> 90:7533-7537 (1993)			
	A286	ROZAKIS-ADCOCK et al., "Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases," <u>Nature</u> 360:689-692 (1992)			
	A287	RUVEDA and GONZALEZ, "Geometric isomerism in benzyldeneoxindoles," <u>Spectrochimica Acta</u> 26A:1275-1277 (1970)			
	A288	RYGAARD and POVLSEN, "Heterotransplantation of a Human Malignant Tumour to 'Nude' Mice," <u>Acta Path. Microbiol. Scand.</u> 77:758-760 (1969)			
	A289	SAINSBURY et al., "Electrochemical Oxidation of Aromatic Ethers. Part 5. ¹ Further Studies of the Coupling Reactions of Alkoxyated Aralkyl- and Aryl-amides," <u>J.C.S. Perkin I</u> 108-114			
	A290	SAITO and STREULI, "Molecular Characterization of Protein Tyrosine Phosphatases," <u>Cell Growth & Differentiation</u> 2:59-65 (1991) *Molecular Biology Journal of the American Association for Cancer Research			
	A291	SANDBERG-NORDQVIST et al., "Characterization of Insulin-Like Growth Factor 1 in Human Primary Brain Tumors," <u>Cancer Research</u> 53:2475-2478 (1993)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 (use as many sheets as necessary)				Complete if Known	
				Prior Application Number	09/741,842
				Prior Appl. Filing Date	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	038602-1607
Sheet	25	of	31		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	A292	SCHINDLER et al., "Über Dibenz[b,f]-azocin-Derivate," <u>Helvetica Chimica Acta</u> 49:985-989 (1966)			
	A293	SCHLESSINGER and ULLRICH, "Growth Factor Signalling by Receptor Tyrosine Kinases," <u>Neuron</u> 9:383-391 (1992) © Cell Press			
	A294	SCHUCHTER et al., "Successful Treatment of Murine Melanoma with Bryostatins 1," <u>Cancer Research</u> 51:682-687 (1991)			
	A295	SEIBERT et al., "Clonal Variation of MCF-7 Breast Cancer Cells <u>in Vitro</u> and in Athymic Nude Mice," <u>Cancer Research</u> 43:2223-2234 (1983)			
	A296	SHAFIE and GRANTHAM, "Role of Hormones in the Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted Into Athymic Nude Mice," <u>J. Natl. Cancer Institute</u> 67:51-56 (1981)			
	A297	SHIBUYA et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family," <u>Oncogene</u> 5:519-524 (1990)			
	A298	SHIRAISHI et al., "Specific inhibitors of Tyrosine-Specific Protein Kinase, Synthetic 4-Hydroxycinnamide Derivatives," <u>Biochemical and Biophysical Research Communications</u> 147:322-328 (1987) © Academic Press			
	A299	SHIRAISHI et al., "Specific Inhibitors of Tyrosine-specific Protein Kinases: Properties of 4-Hydroxycinnamide Derivatives <u>in Vitro</u> ," <u>Cancer Research</u> 49:2374-2378 (1989)			
	A300	SHWEIKI et al., "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," <u>Nature</u> 359:843-845 (1992)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Prior Application Number	09/741,842
				Prior Appl. Filing Date	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	038602-1607
Sheet	26	of	31		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	A301	SINGH et al., "Indolinone Derivatives as Potential Antimicrobial Agents," <u>Zentralbl. Mikrobiol.</u> 144:105-109 (1989) copyright VEB Gustav Fischer Verlag Jena		
	A302	SINGH et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxospiro (Azetidin-3', 4-Indol-2' Ones)," <u>Bollettino Chimico Farmaceutico</u> 133:76-79 (1994)		
	A303	SKEHAN et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," <u>J. Natl. Cancer Inst.</u> 82:1107-1112 (1990)		
	A304	SLAMON et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer," <u>Science</u> 244:707-712 (1989)		
	A305	SOLDI et al., "Platelet-Activating Factor (PAF) Induces the Early Tyrosine Phosphorylation of Focal Adhesion Kinase (p125 ^{FAK}) in Human Endothelial Cells," <u>Oncogene</u> 13:515-525 (1996) copyright Stockton Press		
	A306	SONGYANG et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," <u>Cell</u> 72:767-778 (1993) © Cell Press		
	A307	SONGYANG et al., "Specific Motifs Recognized by the SH2 Domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk and Vav," <u>Molecular and Cellular Biology</u> 14:2777-2785 (1994) © American Society for Microbiology		
	A308	SPADA, et al., "Small molecule inhibitors of tyrosine kinase activity," <u>Expert Opinion on Therapeutic Patents</u> 5:805-817 (1995) ©Ashley Publications		
	A309	STETINOVA et al., "Stereochemistry and Photoisomerisation of Furfurylideneoxindoles," <u>Collection Czechoslov. Chem. Commun.</u> 42:2201-2206 (1977)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

Date Submitted: June 23, 2003

(use as many sheets as necessary)

Complete if Known

Prior Application Number	09/741,842
Prior Appl. Filing Date	12/22/2000
First Named Inventor	Ken Lipson
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	038602-1607

Sheet 27 of 31

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A310	STOLLE, Beilstein Reg. No. 273650, <u>J. Prakt. Chem.</u> , Vol. 2, page 128 (1930)	
	A311	STOLLE, Beilstein Reg. No. 305045, <u>J. Prakt. Chem.</u> , Vol. 2, page 128 (1930)	
	A312	SUMPTER and MILLER, "Chapter IV – Oxindole," in <u>Heterocyclic Compounds With Indole and Carbazole Systems</u> , © Interscience Publishers, Inc., New York, pp. 134-153 (1954)	
	A313	SUN et al., "Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl) methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases," <u>Journal of Medicinal Chemistry</u> 42: 5120-5130 (1999) ©American Chemical Society	
	A314	SUN et al., "Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases," <u>J. Med. Chem.</u> 41:2588-2603 (1998) ©The American Chemical Society	
	A315	SUPERTI-FURGA et al., "A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases," <u>Nature Biotech.</u> 14:600-605 (1996)	
	A316	SUPERTI-FURGA et al., "Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src," <u>EMBO J.</u> 12:2625-2634 (1993) © Oxford University Press	
	A317	TACCONI and MARINONE, "Preparazione e caratteristiche di alcuni 3-ossindolidenderivati," <u>Ricerca Scientifica</u> 38:1239-1244 (1968)	
	A318	TACCONI et al., "(Z)- and (E)-3-Alkylidene-1,3-dihydroindol-2-ones: Influence of Configuration on the Transmission of the Inductive Effect to the Carbonyl Group," <u>J.C.S. Perkin II</u> 150-154 (1976)	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 <i>(use as many sheets as necessary)</i>				Prior Application Number	09/741,842	
				Prior Appl. Filing Date	12/22/2000	
				First Named Inventor	Ken Lipson	
				Group Art Unit	Unassigned	
				Examiner Name	Unassigned	
Attorney Docket Number	038602-1607					
Sheet	28	of	31			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A319	TAKANO et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits Protein Kinase C," <u>Mol. Bio. Cell</u> 4:358A at abstract no. 2076 (1993)	
	A320	TERRETT et al., "Combinatorial Synthesis - The Design of Compound Libraries and their Application to Drug Discovery," <u>Tetrahedron</u> 51(30):8135-8173 (1995) copyright Pergamon! all even pages missing!	
	A321	THIO et al., "The Interconversion of 2-(2-Aminophenyl)-3-piperolidinone and 3-(2-piperidylmethyl)-2-indolinone: A Reversible N = N' Transacylation," <u>Notes</u> (1971) 479-482	
	A322	THOMPSON et al., "Facile Dimerisation of 3-Benzylideneindoline-2-thiones," <u>J. Chem. Soc. Perkin Trans. (I)</u> 1835-1837 (1993)	
	A323	TORP et al., "Expression of the Epidermal Growth Factor Receptor Gene in Human Brain Metastases," <u>APMIS</u> 100:713-719 (1992)	
	A324	TRAXLER, "Protein tyrosine kinase inhibitors in cancer treatment," <u>Expert Opinion on Therapeutic Patents</u> 7(6):571-588 (1997) © Ashley Publications Ltd.	
	A325	TSAI et al., "The Effect of 3,3-Di-Pyridyl Methyl-1-Phenyl-2-Indolinone on the Nerve Terminal Currents of Mouse Skeletal Muscles," <u>Neuropharmacology</u> 31:943-947 (1992) ©Pergamon Press	
	A326	TUZI et al., "Expression of growth factor receptors in human brain tumours," <u>Br. J. Cancer</u> 63:227-233 (1991)	
	A327	TWAMLEY-STEIN et al., "The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells," <u>Proc. Natl. Acad. Sci. USA</u> 90:7696-7700 (1993)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 (use as many sheets as necessary)				Complete if Known	
				Prior Application Number	09/741,842
				Prior Appl. Filing Dat	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	038602-1607
Sheet	29	of	31		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	A328	ULLRICH and SCHLESSINGER, "Signal Transduction by Receptors with Tyrosine Kinase Activity," <u>Cell</u> 61:203-212 (1990) copyright Cell Press		
	A329	VAISMAN et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," <u>J. Biol. Chem.</u> 265:19461-19466 (1990) © The American Society for Biochemistry and Molecular Biology		
	A330	VARMA and GUPTA, "Nucleophilic Reactions of 2-Methyl-3-(4'-carbomethoxyphenyl)-4-quinazolinones with 2-Indolinones," <u>J. Indian Chem. Soc.</u> 66:804-805 (1989) © The Indian Chemical Society		
	A331	VOLLER et al., "Ch. 45 – Enzyme-Linked Immunosorbent Assay," in <u>Manual of Clinical Immunology</u> , 2 nd edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C., pp. 359-371 (1980); @ American Society for Microbiology		
	A332	WAHL et al., "3-benzilidene-5-methyl-1,3-dihydroindol-2-one," <u>Ann. Chim.</u> 350 (1926), DATABASE CROSSFIRE, Beilstein Reference No. 2-21-00-00290		
	A333	WAHL et al., "Chimie Organique - Sur les iso-indogenides," <u>C.R. Hebd. Seances Acad. Sci.</u> 149:132-134 (1909)		
	A334	WAHL, Beilstein Reg. No. 191439, <u>Bull. Soc. Chim. Fr.</u> , page 1038 (1909)		
	A335	WAHL, Beilstein Reg. No. 231732, <u>Bull. Soc. Chim. Fr.</u> , pages 1035-1038 (1909)		
	A336	WALKER, "Synthesis of a α -(p-Aminophenyl)- and α -(p-Chlorophenyl)- β -aryl-propionitriles by Catalytic Reduction of Stilbenenitriles," <u>J. Med. Chem.</u> 8:583-588 (1965)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 <i>(use as many sheets as necessary)</i>		Prior Application Number	09/741,842
		Prior Appl. Filing Date	12/22/2000
		First Named Inventor	Ken Lipson
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Attorney Docket Number	038602-1607		
Sheet	30	of	31

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A337	WALKER et al., "Synthesis of New 3-(Pyridylmethylene)-, 3-(Pyridylmethyl)-, 3-(Piperidylmethyl)-, and 3-(β-Alkylaminoethyl)-2-indolinones. The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>J. Med. Chem.</u> 8:626-637 (1965)	
	A338	WARRI et al., "Estrogen Suppression of erbB2 Expression is Associated with Increased Growth Rate of ZR-75-I Human Breast Cancer Cells <u>In Vitro</u> and in Nude Mice," <u>Int. J. Cancer</u> 49:616-623 (1991) © Wiley-Leiss, Inc.	
	A339	WEIDNER et al., "Tumor Angiogenesis and Metastasis -- Correlation in Invasive Breast Carcinoma," <u>New England J. Medicine</u> 324:1-7 (1991) © Massachusetts Medical Society	
	A340	WINKELMANN et al., "Chemotherapeutically Active Nitro Compounds: 4. 5-Nitroimidazoles (Part I)," <u>Arzneim.-Forsch./Drug Res.</u> 27:2251-2263 (1977)	
	A341	WRIGHT et al., "Cyclic Hydroxamic Acids Derived from Indole," <u>J. Am. Chem. Soc.</u> 78:221-224 (1956)	
	A342	WRIGHT et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," <u>J. Cellular Physiology</u> 152:448-457 (1992)	
	A343	YOUNG and BABBITT, "2-(2-Methyl-3-indolyl)-1,4-benzoquinone, a Reversible Redox Substrate at the Carbon-Paste Electrode in Acidic Aqueous-Ethanol Media," <u>J. Org. Chem.</u> 47:1571-1572 (1982) copyright Am. Chem. Soc.	
	A344	ZAMAN et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor β-Receptor (β-PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," <u>Biochemical Pharmacology</u> 57:57-64 (1999) ©Elsevier Science Inc.	
	A345	ZHANG et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," <u>Molecular Pharmacology</u> 49:228-234 (1996) ©The American Society for Pharmacology and Experimental Pharmaceutics	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: June 23, 2003 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Prior Application Number	09/741,842
				Prior Appl. Filing Date	12/22/2000
				First Named Inventor	Ken Lipson
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	038602-1607
Sheet	31	of	31		

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Indicate the year of the reign of the Emperor in the case of Japanese patent documents. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.